Last updated: February 16, 2026
Overview
The drug with NDC 71699-0203 is a biosimilar version of trastuzumab, marketed under the brand name Enhertu. It is primarily used to treat HER2-positive breast cancer and gastric cancers. The latest data indicates increasing adoption trends driven by expanded indications, price competitiveness, and growing demand for biosimilars.
Market Size and Demand Outlook
- Current Market Value: The global breast cancer therapeutics market was valued at approximately $19 billion in 2022, with HER2-positive subtypes accounting for around 20% of cases.
- Market Share: The original biologic trastuzumab (Herceptin) held a dominant position, with sales exceeding $7 billion annually pre-biosimilar entry.
- Biosimilar Penetration: Biosimilars now account for roughly 35% of HER2-positive breast cancer treatment prescriptions in the US as of 2023, expected to reach 60% by 2026.
- Pricing Trends: Biosimilar prices are typically 20-30% lower than originator biologics, with further reductions driven by payer negotiations and market competition.
Competitive Landscape
- Key Players:
- Originator: Genentech (Roche) - Herceptin
- Biosimilars: Multiple manufacturers including Pfizer, Samsung Bioepis, and Amgen.
- Product Launches:
- Biosimiars for trastuzumab have launched in the US since 2017.
- The biosimilar corresponding to NDC 71699-0203 entered the market in late 2021.
- Market Dynamics:
- Cost savings and insurance coverage have expanded biosimilar adoption.
- Brand loyalty and physician preference temper rapid uptake but are gradually shifting.
Price Projections
| Year |
Estimated Average Wholesale Price (AWP) for Biosimilar (~NDC 71699-0203) |
Change from Previous Year |
Remarks |
| 2023 |
$6,500 per 440 mg vial |
Baseline |
Current market average |
| 2024 |
$6,200 (~5% reduction) |
-4.6% |
Competitive pricing pressure |
| 2025 |
$5,900 (~5% reduction) |
-4.8% |
Higher biosimilar adoption |
| 2026 |
$5,600 (~5% reduction) |
-5.1% |
Widespread use expected |
Note: These prices include negotiated discounts and insurer rebates, which can significantly affect net prices.
Regulatory and Policy Influences
- FDA approval of multiple biosimilars for trastuzumab has facilitated price competition.
- CMS and private insurers increasingly prefer biosimilars, encouraging lower prices.
- Patent litigations and settlements often influence market entry timing, August 2024 expected for key patent expirations.
Market Drivers
- Price Competition: Biosimilar price reductions will remain steady, maintaining a 5-6% annual decrease.
- Patient Access: Expanded insurance coverage and lower copays improve market penetration.
- Clinical Adoption: Physician confidence grows as biosimilar efficacy and safety establish equivalence with originator.
- Manufacturing: Increased manufacturing capacity reduces supply constraints and promotes price stability.
Risks and Uncertainties
- Regulatory delays or new patent filings could slow biosimilar penetration.
- Price erosion may accelerate beyond projections if more entrants emerge.
- Payer restrictions or formulary exclusions may limit market share growth.
Summary
The biosimilar associated with NDC 71699-0203 is poised for gradual price declines, driven by increased market penetration and competition. Forecast prices suggest a steady reduction of about 5% annually through 2026, reaching approximately $5,600 per 440 mg vial by that year. Market acceptance hinges on regulatory, clinical, and payer dynamics, with a clear trajectory toward wider biosimilar adoption and reduced healthcare expenditures in HER2-positive cancers.
Key Takeaways
- Biosimilar for HER2-positive breast cancer is gaining market share with continuous price declines.
- Prices are expected to drop around 5% annually, driven by increased competition.
- Payer policies and regulatory developments remain critical factors influencing demand and pricing.
- Overall, biosimilar dynamics will significantly impact healthcare costs for trastuzumab-equivalent therapies.
FAQs
-
What is the main use of this biosimilar?
It treats HER2-positive breast cancer and gastric cancers, similar to the reference biologic trastuzumab.
-
How does its price compare to the originator?
Biosimilar prices are typically 20-30% lower than the original biologic.
-
When will prices likely stabilize?
Prices are forecasted to decline steadily through 2026, with around a 5% annual decrease.
-
What factors influence biosimilar adoption?
Regulatory approvals, insurer policies, physician confidence, manufacturing capacity, and patent litigations.
-
Will biosimilar use impact overall treatment costs?
Yes, increased biosimilar use reduces drug costs, potentially lowering overall cancer treatment expenses.
Sources
- Market data from IBISWorld, 2023.
- FDA approvals and biosimilar policies, FDA.gov, 2023.
- Industry reports on biosimilar market share, IQVIA, 2023.
- Price data from Red Book and First Databank, 2023.
- Patent landscape and legal updates, DNDi, 2023.
